NasdaqCM - Nasdaq Real Time Price USD

Lakewood-Amedex Biotherapeutics, Inc. (LABT)

0.1809 -0.0191 (-9.55%)

As of 10:14:35 AM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

PR Newswire 12d ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

PR Newswire 26d ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

PR Newswire 1mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

PR Newswire 1mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

PR Newswire 1mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

PR Newswire 1mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

PR Newswire 1mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

NewMediaWire 2mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

PR Newswire 3mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

PR Newswire 3mo ago

LABT
-9.55%
CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics

Zacks Small Cap Research 3mo ago

LABT
-9.55%
Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

PR Newswire 3mo ago

LABT
-9.55%

Performance Overview

Return	LABT	S&P 500 (^GSPC)
YTD	-99.75%	+10.73%
1-Year	-99.75%	+11.11%
3-Year	-99.75%	+81.91%

U.S. markets close in 5h 35m

Lakewood-Amedex Biotherapeutics, Inc. (LABT)

Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

CEO Chat with Dr. Kelvin Cooper, CEO of Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance